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Indian post-kala-azar dermal leishmaniasis (PKDL) is a low-frequency (5–10%) dermal sequela of visceral
leishmaniasis (VL) caused by Leishmania donovani; importantly, affected individuals are speculated to be
parasite reservoirs. Insight into its immunopathogenesis could translate into rational immunomodulatory
therapeutic approaches against leishmaniases. In patients with PKDL (n¼ 21), peripheral lymphocytes were
analyzed for surface markers, intracellular cytokines, and lymphoproliferative responses using flow cytometry.
In lesional tissue biopsies (n¼ 12), expression of counter-regulatory cytokines (IFN-g and IL-10) and the
T-regulatory transcription factor forkhead box protein 3 (Foxp3) was analyzed using reverse transcriptase-PCR,
along with immunohistochemical detection (n¼ 8) of CD3 and Foxp3 positivity. In patients with PKDL,
circulating CD8þCD28 and antigen-induced IL-10þCD3þ lymphocytes were increased and receded with
treatment. CD8þ lymphocytes showed impaired proliferative responses to L. donovani antigen (LDA) and
phytohemagglutinin, which were reinstated after treatment. At presentation, the upregulated lesional IFN-g and
IL-10 messenger RNA (mRNA), Foxp3 mRNA, and protein were curtailed after treatment. In Indian patients with
PKDL, increased frequency of the CD8þCD28 phenotype, enhanced antigen-specific IL-10 production, and
accompanying anergy of circulating lymphocytes suggest their regulatory nature. Furthermore, the
concomitantly elevated lesional expression of Foxp3 suggests their possible recruitment into the lesional site,
which would sustain disease pathology.
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INTRODUCTION
Post-kala-azar dermal leishmaniasis (PKDL), first described
by Brahmachari (1922), presents as a dermal rash after cure of
visceral leishmaniasis (VL) and is caused by the protozoan
parasite Leishmania donovani (Zijlstra et al., 2000; Ramesh
et al., 2007). PKDL is primarily reported from two
VL-endemic regions, the Indian subcontinent and Sudan
and its adjoining areas. In the Indian variant, only 5–10% of
patients with VL acquire PKDL, as opposed to 50–60% in
Sudan (Zijlstra et al., 2003; Ramesh et al., 2007); importantly,
with zoonotic hosts yet to be defined, patients with PKDL are
the proposed parasite reservoirs (Zijlstra et al., 2003).
In the Indian subcontinent, immunological factors predis-
posing patients with VL to PKDL remain poorly character-
ized, with the disease pathology often being attributed to
parasite-specific cell-mediated immune (CMI) responses
(Ramesh et al., 2007). Sudanese patients with PKDL respond
to Leishmania antigen (Ismail et al., 1999), whereas studies
on immune responses in Indian PKDL are not so clearly
defined and even contradictory (Haldar et al., 1983; Neogy
et al., 1988). Our previous study on intracellular cytokine
expression within circulating lymphocytes of patients with
PKDL indicated that generalized CMI was restored but
antigen-specific CMI was restricted to CD3þCD8þ lympho-
cytes producing IL-10 (Ganguly et al., 2008). In this study, we
describe downstream CMI responses in patients with PKDL
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vis-a`-vis cured VL patients and healthy controls by measuring
mitogen-induced and antigen-specific proliferation in circu-
lating CD4þ and CD8þ lymphocytes.
Lesions in PKDL typically present as hypopigmented
macules, nodules, and papules. In Sudanese PKDL, the
incidence of papular or nodular rash is maximal followed by
maculopapular, micropapular, and macular lesions (Zijlstra
et al., 2000), whereas Indian patients report erythema and
induration on the face or numerous, hypopigmented macules
(Ramesh and Mukherjee, 1995; Zijlstra et al., 2003).
Regardless of the differences, the nodular, macular, and
maculopapular lesions predominate and are construed as
hallmarks of PKDL (Zijlstra et al., 2003).
The sustained lesional expression of counter-regulatory
cytokines in patients with PKDL (Ansari et al., 2006) suggests
a role for regulatory T cells (TRegs) who by maintaining
immune homeostasis can regulate immunity to infection
(Sakaguchi, 2004). TRegs comprise 5–10% of the circulating
CD4þ T-cell population and uniquely express the transcrip-
tion factor, Forkhead Box P3 (Foxp3), which is indispensable
for their development and function (Shevach et al., 2006). In
acute infections, TRegs benefit the host by thwarting immune-
mediated pathology after pathogen eradication, whereas in
chronic infections their activity is detrimental to the host, as
they promote parasite survival amidst an active immune
response (Belkaid, 2007). Therefore, in PKDL, the chronic
nature of the disease warrants an analysis into the possible
role of TRegs.
RESULTS
Study population
Patients with PKDL (n¼ 21) were classified as polymorphic,
macular, or papulonodular. All patients tested positive with the
rK39 test and ELISA for anti-leishmanial antibodies; only two
patients (one macular and one papulonodular) tested negative
for L. donovani bodies in skin smears. The majority presented
with polymorphic (n¼18, 85%) followed by papulonodular
(n¼2, 10%) and macular lesions (n¼ 1, 5%) (Table 1);
five patients (24%) gave no previous history of VL attributable
to poor documentation, inability to recall past incidence of
VL, or the subclinical nature of VL. However, they were
included as they had demonstrable L. donovani bodies and
tested positive by rK39 and ELISA. In the remaining 16
patients, the time interval between cure of VL and onset of
PKDL ranged from 1 to 49 years (Table 1). The time interval
often extends to decades (Ramesh and Mukherjee, 1995);
only one patient reported an interval of 49 years, four had an
interval within 17–19 years, whereas the majority (n¼11)
reported an interval from 1 to 3 years. However, no
correlation was evident between time interval and lesional
profiles.
Circulating CD8þCD28 lymphocytes elevated in patients with
PKDL
In patients with PKDL, proportions of circulating
CD4þCD25þ lymphocytes, representing natural T regula-
tory cells, were comparable with healthy controls (Table 2).
However, CD8þCD28 regulatory lymphocytes were sig-
nificantly raised in patients with PKDL when compared with
healthy controls; treatment effected a significant decrease,
values being comparable with healthy controls (Table 2).
With regard to the costimulatory molecule CD28, both
CD4þ and CD8þ lymphocytes in patients with PKDL
showed significant downregulation at presentation when
Table 1. Clinical features of study population
PKDL (n¼21)
Age (years) 30.43±14.28
(Median; range) (30; 12–65)
Sex ratio (M:F) 18:3
Lesional type Polymorphic: 18
Macular: 1
Papulonodular: 2
History of VL 76% (16/21)
Interval between cure of VL and onset (year)
(median; range)
9.57±13.21 (2; 1–49)
Abbreviations: F, female; M, male; PKDL, post-kala-azar dermal
leishmaniasis; VL, visceral leishmaniasis.
Values are mean±standard deviation. Median and range values are in
parentheses.
Table 2. Surface marker and intracellular cytokine
profiles of patients with PKDL
Surface marker/ PKDL Healthy
intracellular cytokine Pretreatment Post treatment controls
Percentage of gated lymphocytes
CD4+CD25+
1
3.72±2.38 3.41±1.74 2.72±1.40
CD4+CD28+
1
22.18±3.86* 33.03±7.18@@ 30.58±6.91
CD8+CD28+
1
11.63±3.64** 16.67±3.70 27.88±3.55
CD8+CD28
1
25.64±4.64*** 17.95±8.19@ 12.05±5.23
CD3+IFN-g+
(LAC stimulated)2
13.86±2.38 13.11±3.26 ND
CD3+IFN-g+
(LDA stimulated)2
0.45±0.21 0.14±0.04 ND
CD3+IL-10+
(LAC stimulated)2
15.26±5.21 11.65±3.71 ND
CD3+IL-10+
(LDA stimulated)2
17.63±4.34 6.29±1.49@ ND
Abbreviations: LAC, leukocyte activation cocktail; LDA, Leishmania
donovani antigen; ND, not determined; PBMC, peripheral blood
mononuclear cell; PKDL, post-kala-azar dermal leishmaniasis.
1Peripheral blood from patients with PKDL (n=21) and healthy controls
(n=6) was stained with surface marker antibodies.
2PBMCs were fixed, permeabilized, and stained with cytokine antibodies.
Cells were acquired using flow cytometry as described in Materials and
Methods, with lymphocytes gated by forward and side scatter.
Values are mean±standard deviation. *Po0.05, **Po0.01, and
***Po0.001 when compared with controls; @Po0.05 and @@Po0.01
when compared with pretreatment.
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compared with healthy controls (Table 2). After treatment,
restoration of CD28 expression was restricted to the CD4þ
subset (Table 3).
Peripheral lymphocytes from patients with PKDL were
unresponsive to L. donovani antigen (LDA)
Specific and generalized CMI were analyzed in terms of
lymphoproliferative responses to LDA and phytohemaggluti-
nin (PHA), respectively. Proliferating cells showed an
expected dilution in carboxyfluorescein diacetate succinimi-
dyl ester fluorescence, whereas unstimulated cells retained
maximum fluorescence, indicating absence of proliferation.
With regard to LDA-induced proliferation, patients with
PKDL showed a poor proliferation index (PI) in both CD4þ
(1.30±0.15) and CD8þ lymphocytes (1.18±0.03). After
treatment, CD4þ lymphocytes showed significantly greater
proliferation than healthy controls (1.95±0.43 vs
1.02±0.01, Po0.05), comparable with cured VL patients
(2.13±0.64). In the CD8þ subset, the post-treatment PI were
more pronounced relative to healthy controls (3.27±1.06 vs
1.01±0.01, Po0.01) and cured VL patients (1.47±0.41,
Figure 1a and c).
In response to PHA, CD4þ lymphocytes from healthy
individuals proliferated strongly, with the PI being
6.70±0.23 (Figure 1b and d). Similarly, patients with PKDL
showed comparable PI before (3.60±0.32) and after treat-
ment (4.26±0.94), whereas patients with VL who had been
cured showed restoration of their characteristically impaired
PI (2.85±0.52). In patients with PKDL, the CD8þ subset
showed impaired proliferation when compared with controls
(4.35±0.65 vs 9.66±0.63, Po0.05), which increased to
7.99±3.17 with treatment, whereas in cured VL patients the
PI remained lower than controls (4.48±1.57, P¼0.09;
Figure 1b and d).
Antigen-specific IL-10 production by proliferating CD3þ
lymphocytes
Generalized and antigen-specific intracellular cytokines in
CD3þ lymphocytes of patients with PKDL were studied. No
differences were observed between pre- and post-treatment
proportions of IFN-g and IL-10 expressing CD3þ cells after
leukocyte activation cocktail stimulation (Table 2). At
presentation, stimulation with LDA in the presence of
Brefeldin A caused minimal production of IFN-g, whereas
Table 3. Immunohistochemistry scores and lesional profiles of patients with PKDL before and after treatment
Patient
Foxp3 score1 CD3 score1
no. Clinical features at presentation Before After Before After
1 Papulonodular lesions emerged chronologically on the
face, trunk, and lower extremities and hypopigmented
macules on the trunk and extremities over a period
of 7 years.
+++ (11.72±2.21) ± (0.30±0.23) +++++ (52.58±1.25) ++++ (41.8±1.35)
2 Erythematous papules and nodules on the face for 1 year;
papules and macules on extremities for 2–3 months.
++ (5.24±1.99) + (1.12±0.64) +++++ (56.4±0.84) ++++ (46.91±0.26)
3 Papulonodules appeared chronologically on the feet,
face, and upper arms and hypopigmented macules on
the trunk and back over a 7-year period.
+ (4.19±0.79) +++ (10.32±2.32) +++++ (53.09±0.73) +++++ (52.58±1.09)
4 Nodular lesions with papules and few disseminated macules
over face, extremities, and upper back for the past 10 years.
+ (1.86±0.24) 0 ++++ (49.72±1.13) ++++ (46.51±1.39)
5 Erythematous plaques and nodules on face, trunk, extremities,
and genitalia for the past 2 and a half years; hypopigmented
macules on trunk and back without sensory abnormality for
the past 2 years.
++ (9.55±1.07) ± (0.42±0.43) +++++ (51.04±3.47) +++++ (53.23±1.86)
6 Hypopigmented macules dispersed all over the body,
prominently on the face, trunk, and extremities for the
past year; micropapules and a few nodules on the
facial region.
+ (1.10±0.55) 0 ++++ (49.19±1.58) ++++ (45.82±1.71)
7 Nodules and papules emerged on the nose, chin, and
pinnae 3 years ago.
+ (2.21±0.65) 0 ++++ (41.64±0.89) ++++ (26.88±0.84)
8 Warty nodules and hypopigmented macular lesions on the
back of the neck, trunk, and upper extremities for the
past 2 years.
++ (6.15±0.83) 0 +++++ (51.05±0.5) +++++ (50.32±0.69)
Abbreviations: Foxp3, forkhead box protein 3; PKDL, post-kala-azar dermal leishmaniasis.
1Paraffin-embedded sections of lesional tissue from patients with PKDL at presentation and after treatment were stained for Foxp3 and CD3 using
immunohistochemistry and scored, as described in Materials and Methods. A positivity score for Foxp3/CD3 was allocated on the basis of the following
scoring index: 0, negative; ±, o1% positive cells; +, 1–5% positive cells; ++, 5–10% positive cells; +++, 10–20% positive cells; ++++, 20–50% positive
cells; and +++++, 450% positive cells.
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Figure 1. Specific and generalized proliferative responses of lymphocytes. Lymphocytes from patients with post-kala-azar dermal leishmaniasis (PKDL) before
(’, n¼ 21) and after (&, n¼ 12) treatment, from patients with visceral leishmaniasis (VL) after cure ( , n¼5), and from healthy controls ( , n¼ 6) were
stained with carboxyfluorescein diacetate succinimidyl ester (CFSE), incubated with/without Leishmania donovani antigen (LDA; 5mgml–1, a) or phytohemagglutinin
(PHA; 10mgml–1, b), and CFSE fluorescence of gated CD3þCD4þ and CD3þCD8þ lymphoblasts was determined using flow cytometry. Columns represent
mean proliferation indices of at least five individuals per group, with error bars denoting SEM. *Po0.05, **Po0.01, significantly different from controls;
@Po0.05, significantly different from VL after treatment. (c) Representative profile of proliferative responses of CD3þCD4þ and CD3þCD8þ lymphocytes
to LDA in patients with PKDL before and after treatment, cured VL patients, and healthy individuals. (d) Representative profile of proliferative responses of
CD3þCD4þ and CD3þCD8þ lymphocytes to PHA in patients with PKDL before and after treatment, cured VL patients, and healthy individuals.
1016 Journal of Investigative Dermatology (2010), Volume 130
S Ganguly et al.
Regulatory T Cells in Indian PKDL
IL-10-producing CD3þ cells were elevated, which were
significantly reduced after treatment (Table 2).
Upregulated lesional expression of IFN-c and IL-10 decreased
with treatment
To elucidate counter-regulatory cytokine profiles in lesional
tissue from patients with PKDL, messenger (mRNA) expres-
sion of IFN-g and IL-10 was quantitated in paired samples. At
presentation (n¼12), a significant upregulation in IFN-g
expression was observed when compared with healthy
controls (1.21±0.08 vs 0.21±0.02, Po0.001); similarly,
IL-10 transcripts were significantly increased (0.44±0.07 vs
0.005±0.002, Po0.001, Figure 2a and c). After treatment, a
significant reduction in both IFN-g (0.50±0.11, Po0.001) and
IL-10 (0.04±0.01, Po0.001) was evident (Figure 2a and b).
Elevated lesional Foxp3 mRNA expression in patients with PKDL
To determine whether increased expression of IL-10 in
lesional tissue was associated with an enhanced presence
of TReg cells, lesional mRNA expression of the TReg
transcription factor, Foxp3, was quantitated. Patients with
PKDL, when compared with healthy controls, had signifi-
cantly upregulated Foxp3 transcripts (0.19±0.05 vs
0.02±0.01, Po0.01; Figure 3a and c); treatment effected a
modest reduction in Foxp3 mRNA levels (0.14±0.05) (Figure
3a–c). On an individual basis, decreased expression was
evident in 9 out of 12 patients, the percentage reduction
ranging from 6.13 to 86.49%; one patient retained the same
level of expression, whereas two showed higher mRNA levels
(Figure 3b).
Increased lesional accumulation of T regulatory cells in patients
with PKDL regressed with treatment
To confirm whether upregulated expression of Foxp3
translated into increased protein, immunohistochemistry
was performed on lesional tissue from patients with PKDL
(n¼8), healthy controls (n¼3), and one patient with
erythema nodosum leprosum; in addition, sections were
stained for CD3. In PKDL lesions, microscopic analysis
showed an accumulation of Foxp3þ cells within a dense and
predominantly CD3þ lymphocytic infiltrate (Figure 4a
and b), whereas healthy skin showed virtually no Foxp3þ
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Figure 2. Longitudinal monitoring of lesional expression of IFN-c and IL-10 in patients with post-kala-azar dermal leishmaniasis (PKDL) before and after
treatment. (a) Representative profile of mRNA expression of IFN-g and IL-10 in lesional tissue from patients with PKDL (n¼ 5) before and after treatment and
normal skin tissue from healthy individuals (n¼3). Isolated RNA was subjected to reverse transcriptase-PCR (RT-PCR); products were resolved using agarose gel
electrophoresis with bands specific for b-actin, IFN-g, and IL-10, visualized using UV transillumination, and quantified using densitometric analysis, as described
in Materials and Methods. (b) Before–after plots of IFN- g and IL-10 expression in patients with PKDL (n¼ 12) before (m) and after completion of treatment (n).
(c) Scatter plots of expression values for IFN-g and IL-10 in patients with PKDL (n¼ 12) before (m) and after treatment (n) as well as in healthy controls
(E, n¼ 3); horizontal lines indicate mean values. *Po0.01, **Po0.001, significantly different from controls; @Po0.001, significantly different from pre-treatment.
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cells, scant CD3þ lymphocytes, and minimal cellular
infiltrate (Supplementary Figure S1 online). In the patient
with erythema nodosum leprosum, Foxp3þ cells were barely
detectable amidst a CD3þ lymphocyte-rich infiltrate (Supp-
lementary Figure S1 online).
At presentation, one patient had a positivity of 10–20%
(Figure 4a), three had a score of 5–10% and four out of eight
patients had Foxp3þ scores of 1–5% (Figure 4b). After
treatment, all patients except one showed a reduction in
Foxp3þ positivity to either o1% or undetectable levels
(Figure 4a and b and Table 3). At presentation, CD3 positivity
ranged from 20 to 50% (n¼3) and to450% (n¼ 5, Figure 4a
and b). After treatment, all except two patients showed no
differences in their proportions of CD3þ lymphocytes (Figure
4a and b and Table 3).
DISCUSSION
In PKDL, enhanced secretion of IL-10 and transforming
growth factor-b by antigen-stimulated peripheral blood
mononuclear cells (PBMCs) has been associated with disease
severity (Saha et al., 2007). Subsequently, we proposed IL-10-
producing antigen-specific circulating CD8þ lymphocytes
together with increased serum IL-10, IgG1, and IgG3 as
markers of Indian PKDL (Ganguly et al., 2008). After antigen
exposure, IL-10 not only influences induction of peripheral
type 1 TReg cells (Groux et al., 1997; Vieira et al., 2004), but it
also serves as the flag bearer of their suppressive activity
(Workman et al., 2009). As antigen-induced TRegs exclusively
produce IL-10 (O’Garra and Vieira, 2004), the involvement of
TRegs in PKDL has previously been proposed (Ganguly et al.,
2008). This study was undertaken to show the presence of
both circulatory and lesional TRegs in a substantial number of
patients with PKDL (Table 1).
In Sudanese PKDL, antigen-specific CMI responses have
been documented (Ismail et al., 1999; Gasim et al., 2000),
whereas in India, reports are varied. Haldar et al. (1983)
reported specific CMI in five out of six patients with newly
acquired PKDL vis-a`-vis three out of six patients with chronic
PKDL, whereas Neogy et al. (1988) recorded an absence of
Leishmania-specific CMI. In this study, patients with PKDL
showed no antigen-induced proliferation of CD4þ lympho-
cytes that was marginally restored after treatment (Figure 1a
and c). However, in cured VL patients, a higher degree of
proliferation was observed, attributable to greater proportions
of antigen-specific memory and residual effector lymphocytes
(Figure 1a and c). With respect to antigen-primed CD8þ
lymphocytes, patients with PKDL again showed an impair-
ment that was also restored after treatment, attributable to the
elevated proportion of CD8þCD28 regulatory lymphocytes
(Table 2).
However, no impairment of generalized CMI has been
reported in Indian PKDL (Haldar et al., 1983; Neogy et al.,
1988), which is corroborated by robust intracellular IFN-g
and IL-2 production (Ganguly et al., 2008). In previous
studies, proliferative responses were examined in bulk
lymphocyte populations (Haldar et al., 1983; Neogy et al.,
1988), thereby overlooking differences in effector lympho-
cyte subsets. Indeed, whereas Neogy et al. (1988) showed
an overall PHA-induced proliferation in Indian patients
with PKDL, this study, using carboxyfluorescein diacetate
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Figure 3. Lesional forkhead box protein 3 (Foxp3) expression in patients with post-kala-azar dermal leishmaniasis (PKDL) at presentation and after treatment.
(a) A representative profile of Foxp3 mRNA expression in lesional tissue from patients with PKDL (n¼5) before and after treatment and normal skin tissue
from three healthy individuals. Expression was quantified using reverse transcriptase-PCR (RT-PCR) and subsequent densitometric analysis, as described in
Materials and Methods. (b) Before–after plot of Foxp3 expression in patients with PKDL (n¼ 12) before (m) and after completion of treatment (n). (c) Scatter
plot showing Foxp3 expression values in patients with PKDL (n¼ 12) before (m) and after treatment (n) and in healthy controls (E, n¼3). Horizontal
lines indicate mean values. *Po0.01, significantly different from controls.
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succinimidyl ester dilution, established differences between
the PHA-specific proliferative capacity of CD4þ and CD8þ
lymphocytes. Pre- and post-treatment CD4þ responses were
comparable with healthy controls and cured VL patients
(Figure 1b and d); however, CD8þ lymphocytes proliferated
weakly vis-a`-vis healthy controls, with the impairment being
corrected after treatment (Figure 1b and d). As CD28
expression and signaling is instrumental in the CD28/B7
costimulatory pathway preventing induction of clonal anergy
(Becker et al., 1995), the elevated CD8þCD28 subset at
presentation in patients with PKDL with the attendant CD28
downregulation on CD8þ lymphocytes, possibly accounts
for the diminished responsiveness of the CD8þ subset to PHA
(Table 2).
In comparison with their CD4þCD25þ major histocom-
patibility complex class II-restricted counterparts, the
class I-restricted CD8þ TRegs remain poorly characterized
(Siegmund et al., 2009). Induced or naturally occurring
CD8þ TRegs include the CD8
þCD28 population that
suppress T-cell activation, not by cell-cell contact, but by
interfering with antigen-presenting cell functions (Liu et al.,
1998). Interestingly, the TReg marker, Foxp3, although not
detectable in peripheral CD8þ cells, can be induced by
in vitro stimulation with anti-CD3 and anti-CD28 or
transforming growth factor-b (Siegmund et al., 2009). In
mice infected with L. major, studies on DNA immunization
have proposed an immunoregulatory role for CD8þ lym-
phocytes (Gurunathan et al., 2000); however, information on
clinical leishmaniases remains limited.
At the intracellular level, carboxyfluorescein diacetate
succinimidyl ester-stained CD3þ lymphocytes were exam-
ined and not CD8þ lymphocytes, owing to a technical
limitation in a four-color assay. In patients with PKDL, after
6 days of antigenic stimulation, increased production of the
potent regulatory cytokine, IL-10, was observed (Table 2).
This finding, in conjunction with our previously reported
increase in intracellular IL-10 within the CD8þ subset from
patients with PKDL (Ganguly et al., 2008), and impaired
CD8þ proliferative responses (Figure 1a and c), supports a
regulatory role for peripheral CD8þ lymphocytes in Indian
PKDL.
As knowledge of the interplay of cytokines within the
lesional site is critical to understanding the immunopathology
of PKDL, gene expression studies were undertaken on paired
lesional biopsies from patients with PKDL. Our study
corroborated reports of high lesional expression of both
IFN-g and IL-10 in Indian PKDL (Ansari et al., 2006); on an
individual basis, all 12 patients showed a significant
reduction in mRNA levels of both cytokines after treatment
(Figure 2), pointing to their involvement in disease pathogen-
esis, with IFN-g possibly being directed against skin-resident
parasites, whereas IL-10 curtailed excessive IFN-g-driven
immune responses. Gene expression studies cannot establish
the cellular source(s) of altered cytokines, more so for a
pleiotropic cytokine such as IL-10, which is secreted by a
plethora of immune cells (O’Garra and Vieira, 2007). The
magnitude of the problem increases manifold if one considers
the cellular profile of the lesional site in PKDL in which its
often-dense inflammatory cell infiltrate can theoretically host
several immune cells. The question of which cellular subset
accounts for the increased lesional IL-10 expression in PKDL
has remained unanswered, thus stoking our interest in
inducible TRegs.
In chronic infections, TRegs are primary sources of IL-10
(Belkaid, 2007). As no information exists on TReg involvement
in PKDL, we examined the role (if any) of TRegs in the
localized immune milieu of PKDL. Expression of the TReg-
exclusive transcription factor, Foxp3, studied both at the
mRNA (Figure 3) and protein levels (Figure 4), yielded a
finding that TRegs feature prominently in the inflammatory
infiltrate (Figures 3 and 4a and b and Table 3); to our
knowledge, this finding has not been reported in PKDL.
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Figure 4. Immunohistochemistry of lesional sections from patients with
post-kala-azar dermal leishmaniasis (PKDL). (a) A representative profile of
CD3 and forkhead box protein 3 (Foxp3; 10–20% positivity) staining in
lesional tissue sections from a patient with PKDL before and after treatment.
(b) A representative profile of CD3 and Foxp3 (1–5% positivity) staining in
lesional tissue sections from a patient with PKDL before and after treatment.
Arrows indicate Foxp3-positive cells within the lymphocytic infiltrate.
Bars¼ 10 mM.
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This accumulation of Foxp3þ TRegs was not simply an
accompaniment of infiltrating CD3þ lymphocytes, as lesions
of a patient with erythema nodosum leprosum, a granulo-
matous reversal reaction of leprosy, showed barely detectable
Foxp3þ cells in a CD3þ lymphocyte-rich lesional milieu
(Supplementary Figure S1 online). Treatment curtailed
accumulation of TRegs as evident by the reduced expression
of Foxp3 (Figure 4a and b and Table 3) affirming their
contribution to lesional pathology, which however was not
evident in the marginal decrease in mean lesional Foxp3
mRNA levels, suggesting a deficiency in translational
mechanisms. Although natural TRegs have a negligible role
in VL with IL-10 expression limited to splenic T cells other
than CD4þCD25þFoxp3þ TRegs (Nylen et al., 2007),
lesional TRegs downregulate effector T-cell responses in
cutaneous leishmaniasis caused by Leishmania braziliensis,
(Campanelli et al., 2006). In addition, in localized cutaneous
leishmaniasis caused by L. guyanensis, treatment refractori-
ness was associated with high lesional Foxp3 expression
(Bourreau et al., 2009a) and lesional TRegs were shown to
suppress IFN-g production by antigen-stimulated peripheral
CD4þCD25 T lymphocytes (Bourreau et al., 2009b),
suggesting that accumulating TRegs by dictating impairment
of local immunity contribute to disease persistence in
leishmaniases.
Collectively, we propose that in patients with PKDL, the
circulating antigen-specific IL-10-producing CD8þ lympho-
cytes (Ganguly et al., 2008) are anergic and endowed with
regulatory ability. These cells upon infiltration into the
lesional site potentially sustain disease progression by
producing IL-10 to counter IFN-g-mediated responses against
parasites. However, specialized immunohistology is neces-
sary to pinpoint whether TRegs are the cellular sources of IL-10
in PKDL, considering that Foxp3 is nuclear in location
whereas IL-10 is cytoplasmic. Future investigations dealing
with their functional profiles, specifically their interaction
with target immune cells within the localized PKDL milieu,
are necessary for the development of immunomodulatory
therapies against PKDL and by extension, the leishmaniases.
MATERIALS AND METHODS
Study subjects
Patients diagnosed with PKDL (n¼ 21) or treated for VL (n¼ 5) were
recruited from the School of Tropical Medicine, Kolkata and Medical
College, Kolkata from 2006 to 2009. Diagnosis was based on
clinical features, a past history of VL, rK39 positivity (Sundar et al.,
2006), ELISA using crude LDA (Chatterjee et al., 1998), and presence
of L. donovani bodies in skin smears. Patients with PKDL received
either sodium stibogluconate (20mg kg–1 day–1 intramuscular for 3
months) or miltefosine (100mgday–1 p.o. for 2 months), whereas
patients with VL had received amphotericin B (1mg kg–1 day–1
intramuscular for 1 month). Remission of clinical features was a
primary criterion of cure; samples were collected at presentation and
1 month after completion of treatment after obtaining informed
consent from the patient or parent/guardian in case of minors. Non-
endemic controls (n¼ 6) were included. The study received previous
approval from the institutional human ethical committee and was
conducted according to the Declaration of Helsinki principles.
Collection of samples
Heparinized blood (12ml) was collected and skin biopsies (4mm)
were extracted from lesional site(s) for (a) immunohistochemistry,
(b) isolation of RNA stored in RNALater (Ambion, Austin, TX)
at 20 1C, and (c) parasite transformation (placed in Schneider’s
insect medium (Sigma-Aldrich, St Louis, MO) supplemented with
20% heat-inactivated fetal calf serum).
Surface marker analysis
Whole blood (100ml) was surface stained with fluorochrome-
conjugated antibodies (CD4 and CD25, CD8 and CD28); lympho-
cytes were gated on a linear forward versus side scatter dot plot and
fluorescence was measured (Ganguly et al., 2008) using CellQuest
Pro software (BD Biosciences, San Jose, CA).
Isolation of peripheral blood mononuclear cells (PBMCs)
Peripheral blood mononuclear cells were isolated as previously
described (Ganguly et al., 2008) and resuspended in RPMI-1640
medium supplemented with penicillin (100Uml–1), streptomycin
(100mgml–1), and 10% heat-inactivated fetal calf serum. Cell
viability (495%) was confirmed using Trypan blue exclusion.
Preparation of L. donovani antigen (LDA)
Antigen was prepared as previously described (Ganguly et al., 2008)
and stored at 20 1C until use.
Lymphoproliferation assay
Peripheral blood mononuclear cells were incubated with carboxy-
fluorescein diacetate succinimidyl ester (10mM in serum-free
medium) at 37 1C in 5% carbon dioxide for 10minutes; the
reaction was terminated on ice for 5minutes, and the cells
were washed, resuspended in RPMI-1640 medium containing 10%
heat-inactivated fetal calf serum (1 106mlwell–1), and incubated
with PHA (10 mgml–1) or LDA (5mg/ml–1) for 6 days at 37 1C in
5% carbon dioxide. They were then harvested, stained with
fluorochrome-conjugated antibodies to CD3 and CD4 for 15min-
utes, and acquired on a BD FACSCalibur flow cytometer using BD
CellQuest Pro software (BD Biosciences). Lymphoblasts were
specifically gated on the blast-characteristic population on a forward
versus side scatter dot plot and further gated on an FL3 (CD3
fluorescence) versus FL2 (CD4 fluorescence) dot plot and a
minimum of 10,000 CD3þ blasts were acquired. Proliferation
indices were determined by curve-fitting analysis on a proliferation
model of ModFit LT software (Verity Software House, Topsham, ME),
in which the marker was set on the parent population in
unstimulated cells.
Intracellular cytokine staining
Peripheral blood mononuclear cells, which were proliferating in
response to PHA (10 mgml–1) or LDA (5 mgml–1), were either
restimulated for the last 4 hours of treatment with leukocyte
activation cocktail containing phorbol myristate acetate (10 ngml–1),
ionomycin (1mM), brefeldin A (10 mgml–1), or exposed to brefeldin A
alone. After harvesting, PBMCs were surface-stained with anti-
human CD3-PerCP, fixed and permeabilized, stained with fluor-
ochrome-conjugated antibodies against IFN-g and IL-10, acquired
on a flow cytometer, and analyzed as previously described (Ganguly
et al., 2008).
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Reverse transcriptase-PCR analysis
Total RNA was isolated from skin lesions according to the
manufacturer’s instructions (RNAqueous-4PCR Kit, Ambion). Re-
verse transcriptase-PCR was performed on isolated RNA (100 ng)
with the one-step reverse transcriptase-PCR kit (Qiagen, Hilden,
Germany) using gene-specific primers for b-actin, IFN-g, IL-10, and
Foxp3 (Supplementary Table S1 online). For reverse transcription,
samples were subjected to an initial incubation at 50 1C for
30minutes followed by an initial PCR activation (95 1C for
15minutes). The amplification cycle comprised 35 cycles of
denaturing (94 1C for 30 seconds), annealing for 30 seconds (varying
temperatures for each primer set; Supplementary Table S1 online),
extension (72 1C for 60 seconds), and a final extension at 72 1C
(10minutes). Products were resolved on agarose gels (2%) contain-
ing ethidium bromide (0.5 mgml–1) and quantified using Total lab
Nonlinear Dynamic Image analysis software (Newcastle, UK), with
the values being normalized to b-actin.
Immunohistochemistry
Immunohistochemical staining was performed as previously des-
cribed (Little et al., 2001). In brief, slide-mounted sections were
boiled in citrate buffer (pH 6.0; for CD3 staining) or Tris-EDTA buffer
(pH 9.0; for Foxp3 staining) for antigen retrieval. Sections were
incubated overnight at 4 1C with a 1:75 dilution of anti-human
Foxp3 (eBioscience, San Diego, CA) or for 1 hour at room
temperature with a 1:100 dilution of anti-human CD3 (Dako,
Glostrup, Denmark) and binding was detected by Super Sensitive
Polymer-horseradish peroxidase Detection system (BioGenex, San
Ramon, CA), following the manufacturer’s instructions. After
addition of the substrate 3-diaminobenzidine tetrahydrochloride
and counterstaining with hematoxylin, the cells that were positive
for DAB or hematoxylin were counted, with three representative
fields per section. A positivity score for Foxp3/CD3 was allocated on
the basis of a scoring index as follows: 0, negative;±,o1% positive
cells; þ , 1–5% positive cells; þ þ , 5–10% positive cells; þ þ þ ,
10–20% positive cells; þ þ þ þ , 20–50% positive cells; and
þ þ þ þ þ , 450% positive cells. Sections were evaluated
independently by two observers and all samples were coded to
minimize bias.
Statistical analysis
For parametric data (determined with the Shapiro–Wilk normality
test), one-way analysis of variance was performed and the
differences between groups were analyzed using Bonferroni’s
multiple comparison test. For non-parametric data, Kruskal–Wallis
analysis of variance followed by Dunn’s multiple comparison test
was used to analyze data for individual groups. All analyses were
performed using GraphPad Prism software (GraphPad Software Inc,
San Diego, CA).
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